Articles On Arc Exploration (ASX:ARX)

The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%. Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has...

Earlier this week the Pinnacle Investment Summit was held and a number of ASX fund managers outlined the stocks they backed. One was Marcus Burns from Spheria Asset Management and he backed one of the ASX’s newest retailers.   Universal Sto...

The cavalcade of life science initial public offers (IPOs) and ASX listings shows few signs of receding, with BCAL Diagnostics (ASX:BDX) last week braving the bourse amid choppy global market conditions. In the life sciences IPO Olympiad, w...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date. Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain,...

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) has announced the successful completion of a $47 million placement to institutional and sophisticated investors.

The ASX tech sector succumbed to the latest selloff in tech equities globally. dragging the rest of the bourse down with it. The ASX 200 retreated 0.7% to close at 7,379 points while the ASX Emerging Companies Index lost 1.06%, closing at 2...

The ASX 200 touched intraday record highs, but could not hold on and closed the day just shy of its all time high. The benchmark index finished 0.46% higher at 7,428, and is now on track to finish July on a 10-month winning streak. Six out...

The fortunes of ASX healthcare shares can often swing on one momentous milestone. Examples of such a make-or-break event could be a breakthrough invention, successful product trial, or regulatory approval (or rejection). Such incidents can...

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

The Aroa Biosurgery Ltd (ASX: ARX) share price is on the move on Tuesday morning. At the time of writing, the soft-tissue regeneration company’s shares are up 1.5% to $1.20. Why is the Aroa Biosurgery share price rising? Investors have be...

The ASX picked up where it left off before the Easter break with another day of gains. The ASX 200 rose 0.84 per cent to 6,886 points and the ASX Emerging Companies Index rose 1.17 per cent, closing at 2,036 points. Utilities and energy wer...

The Aroa Biosurgery Ltd (ASX: ARX) share price is up 2.6% after the company shared positive news this morning. A new product from the soft-tissue regeneration company has received US Food and Drug Administration (FDA) clearance. At the tim...

Source: Monster Ztudio, Shutterstock Summary Allegra Orthopaedics has reported completing the 8-week timeline for the large animal pilot study for its Spinal Cage Device. Soft-tissue regeneration company Aroa Biosurgery has obtained F...

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) has announced the US FDA has granted 510(k) clearance for its Myriad Morcells.

ASX mid-cap healthcare company Avita Medical Inc (ASX: AVH) released its second-quarter FY21 results to the market last week. Despite recording positive revenue numbers, the Avita share price has continued to slide lower over the last five...

Shares in ASX healthcare company Polynovo Limited (ASX: PNV) almost doubled in price last year. And, despite a shaky start to 2021, at their current price of $2.62 they are still up over 100% versus their March 2020 low of $1.275. For inve...

New ASX stocks are beating the old in 2020 and some experts are predicting that this will trigger an IPO revival this year. Initial public offering (IPO) platform OnMarket found that year-end IPOs outperformed the  S&P/ASX 200 Index (I...

Peter Switzer is joined by Brian Ward, the founder and CEO of soft tissue regeneration company Aroa (ARX).

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) says the Indian regulator has approved three of its products based on the ECM platform.

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) could be about to end its winning streak. The benchmark index is currently down 0.15% to 6,673.1 points. Four shares that have fallen more than most today are listed below. Here’s why...

Shares in soft tissue regeneration company, Aroa Biosurgery Ltd (ASX: ARX), are falling lower this morning after the company reported a 10% decline in revenue for the first half of FY21. At the time of writing, the Aroa Biosurgery share pr...

On Tuesday Pinnacle Investment Management Group Ltd (ASX: PNI) held its Pinnacle 2020 Virtual Summit, with a number of leading fund managers sharing their views on the small cap sector. Four small cap ASX shares that were picked out by fun...

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) has provided an update it says highlights the recovery in its sales that were impacted by the COVID-19 pandemic in the June quarter. 

The sudden drop in spot gold prices and reintroduction of COVID-19 restrictions in New Zealand have hit the relevant ASX small caps this morning. After 100 days of being virus-free, four COVID-19 cases were detected in the country. New Zeal...

ASX companies continued to raise money in July, with over $4bn shelled out by investors, taking 2020’s total above $30bn. According to Bloomberg, there has been $32.3bn worth of cash raised between January 1 and August 3. This is well ahead...

The Aroa Biosurgery Ltd (ASX: ARX) share price has closed 7.69% higher today after announcing it has secured United States Food and Drug Administration (FDA) clearance for one of its products, ‘Symphony’. In addition, the company received...

Shareholders in biological scaffold maker Aroa Biosurgery (ASX:ARX) got a double treat on Thursday morning after the company received both FDA and European regulator approvals. The Auckland headquartered company makes and sells products bas...

Newly-listed soft tissue regeneration company Aroa Biosurgery (ASX: ARX) has announced that its Symphony and Myriad complex wound healing products have gained clearance from international regulators. Symphony has received approval from the...

Aroa Biosurgery Ltd (ASX: ARX) knocked the lights out on its ASX opening day debut on Friday. The New Zealand-based medical company entered the Australian market on the final day of trading last week. It sold 40 million new shares at an in...

There are many reasons why a company might change its name, from being taken over to hiding a shady past. This year 114 companies have changed their name. Family cyber security provider Wangle Technologies became the much more fitting Famil...

Base metals explorer Cyprium Metals (ASX: CYM) has reported positive results from a drilling campaign at the Hollandaire and Hollandaire West targets within the Cue copper project in WA’s Murchison district. The campaign involved drilling t...